title: Increased activity of superoxide dismutase in advanced stages of head and neck squamous cell carcinoma with locoregional metastases.
abstract: The aim of the study was to investigate relationship between activity of superoxide dismutase (SOD), malondialdehyde (MDA) and tumor necrosis factor alpha (TNFalpha) and between Ala-9Val polymorphism in the gene encoding MnSOD (SOD2) and the initial stage and prognosis of the head and neck squamous cell carcinoma (HNSCC). Prospective study cohort comprised 88 patients who underwent surgical treatment for the diagnosis of HNSCC (53 patients were diagnosed with locoregional metastatic spread (N+) at the time of diagnosis). After the initial surgery subjects were followed for the subsequent period of 26 months during which 14 manifested relapse. Genotypes were detected by the PCR-based methodology. Activity of p-SOD, ery-SOD and TNFalpha were determined by ELISA, and the concentration of MDA by high performance liquid chromatography. Genotype and allele frequencies of the Ala-9Val differed neither between groups defined according to the stage of primary disease (TNM), nor between relapse vs. remission groups after the follow-up (p>0.05). Activity of p-SOD was significantly higher in T3/4 stage compared to T1/2 (p=0.01) and was also higher in N+ compared to N0 patients (p=0.002). Carriers of the Ala/Ala genotype had higher p-SOD activity (p=0.04). There was no significant difference in DFI between SOD2 genotype groups (p>0.05), however, the Ala/Ala group exhibited the shortest median DFI. In conclusion, our results suggest that increased p-SOD at the time of the initial treatment for HNSCC is connected with greater extent and nodal metastatic spread of the initial disease and with an earlier relapse of the disease. Progression of the disease might be further modified by the presence of Ala/Ala genotype of the SOD2. Activity of p-SOD could thus offer diagnostic as well as prognostic value.
authors.affiliation: Dept. of Otorhinolaryngology and Head & Neck Surgery, St. Anne's Faculty Hospital, Czech Republic. rikisali@gmail.com
authors.forename: R
authors.initials: R
authors.lastname: Salzman
authors.forename: K
authors.initials: K
authors.lastname: Kanková
authors.forename: L
authors.initials: L
authors.lastname: Pácal
authors.forename: J
authors.initials: J
authors.lastname: Tomandl
authors.forename: Z
authors.initials: Z
authors.lastname: Horáková
authors.forename: R
authors.initials: R
authors.lastname: Kostrica
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000235:genetics / Q000556:secondary; D015331:Cohort Studies; D004912:Erythrocytes / Q000201:enzymology*; D005260:Female; D005838:Genotype; D006258:Head and Neck Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D009367:Neoplasm Staging; D018384:Oxidative Stress; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D013482:Superoxide Dismutase / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D015996:Survival Rate; D016896:Treatment Outcome; D000099156:Superoxide Dismutase 2